c

|  |  |
| --- | --- |
| **Pharmacy and Therapeutics Committee**  Virtual Meeting  January 24, 2024  12:00 PM - 5:00 PM | |
| **Zoom Registration Link -** [**https://ahcccs.zoom.us/webinar/register/WN\_rm-o36stQ5uEu\_rS\_oCKUA**](https://ahcccs.zoom.us/webinar/register/WN_rm-o36stQ5uEu_rS_oCKUA) | |
| **Time** | **Topic** |
| **12:00 PM** | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:10 PM** | **Minutes Review and Vote - P&T October 25, 2023:** Suzanne Berman, RPH, AHCCCS Pharmacy Director |
| **12:15 PM** | **Nineteen Non-Supplemental Rebate Drug Class:** Clinical review by Hind Douiki, PharmD, Magellan   1. **Androgenic Agents**    1. Public Testimony: None 2. **Antidepressants, Other**    1. Public Testimony: None 3. **Antidepressants, SSRIs**    1. Public Testimony: None 4. **Antivirals, Topical**    1. Public Testimony: None 5. **Bone Resorption Suppression and Related Agents**    1. Public Testimony: None 6. **Bronchodilators, Beta Agonists**    1. Public Testimony: None 7. **Colony Stimulating Factors**    1. Public Testimony: None 8. **Enzyme Replacement Products, Gaucher Disease**    1. Oral Public Testimony: None    2. Written Public Testimony:       1. Aviva Rosenberg 9. **Erythropoiesis Stimulating Proteins**    1. Public Testimony: None 10. **Hypoglycemics, Alpha Glucosidase Inhibitors**     1. Oral Public Testimony: None 11. **Hypoglycemics, Metformins**     1. Public Testimony: None 12. **Hypoglycemics, SGLT2s**      1. Public Testimony: None 13. **Immunoglobulins**     1. Oral Public Testimony: None     2. Written Public Testimony:        1. Matthew Prentice 14. **Oncology, Oral - Hematologics**      1. Public Testimony: None 15. **Ophthalmics, Anti-inflammatory/Immunomodulators**     1. Public Testimony: None 16. **Oral and Inhaled Pulmonary Arterial Hypertension Agents**     1. Oral Public Testimony:        1. Naomi Habib        2. Debby Dunaway 17. **Otic Antibiotics**     1. Public Testimony: None 18. **Thrombopoiesis Stimulating Agents**      1. Public Testimony: None 19. **Ulcerative Colitis**     1. Public Testimony: None |
|  |  |
| **2:00 PM** | **New Drug Reviews: Hind Douiki,** PharmD, Magellan   1. Bimzelx - Bimekizumab 2. Daybue - Trofinetide 3. Jesduvroq - Daprodustat 4. Omvoh - Mirikizumab 5. Skyclarys - Omaveloxolone    1. Oral Public Testimony:       1. Elizabeth Mucklow       2. Michael Wolfson       3. Lynda Finch    2. Written Public Testimony:       1. Jen Farmer 6. Velsipity - Etrasimod arginine 7. Zurzuvae - Zuranolone    1. Oral Public Testimony:       1. Lynda Finch    2. Written Public Testimony:       1. Cindy Lee Herrick       2. Carmen Koiscek |
| **2:45 PM** | **Break & Executive Session:** Kristen Haloski**,** PharmD, AAHIVP, Magellan |
| **4:15 PM** | **Public Therapeutic Class Votes:** Hind Douiki, PharmD, Magellan |
| **4:45 PM** | **Biosimilar Update: Suzi Berman** |
| **4:50 PM** | **Meeting Adjournment**  **Future Meeting Dates:**  May 21, 2024  October 15, 2024  January 25, 2025 |